FiercePharma

Novartis debuts €40M viral vector plant in Slovenia, part of €3.5B investment push in the country

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 million ($41.2 million) viral vector facility in Mengeš, Slovenia. The new ...
GEN

Digital Twin Focuses on Improving Viral Vector Production

A mathematical model could help reduce the experimental effort needed to develop production processes for gene therapies. The digital twin, developed by a team at University College London (UCL) in ...
GEN

Successful Scale-Up of an Upstream Viral Vector Process Using an Adherent Platform

Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. To meet patient needs, reliable and cost-effective ...
STAT

Cost and scalability key drivers of expanded gene therapy access

From rare diseases to common chronic conditions, advances in viral vector-based gene therapies are bringing exciting new clinical possibilities to the table. But current costs per dose land as high as ...
Nasdaq

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology ...